Supplementary Table S4 shows breast cancer-specific survival in patients with invasive ductal carcinoma vs. invasive lobular carcinoma with known HER2 status in different time periods (0–5 years and 5–10 years). Model A is adjusted for histology and clinicopathological features; Model B is adjusted for histology, clinicopathological features, and treatment modalities. Model C is adjusted for histology, clinicopathological features, treatment modalities and socioeconomic status. Abbreviations: HR, hazard ratio: CI, confidence interval.
ARTICLE ABSTRACT
Invasive lobular carcinoma (ILC) exhibits differences in molecular and biological characteristics compared with invasive ductal carcinoma (IDC). We aim to compare breast cancer–specific survival (BCSS) between patients with ILC and IDC.
We used data from the Surveillance, Epidemiology, and End Results database (1992–2020). Logistic regression analyses were conducted to identify factors associated with treatment modalities. We examined BCSS at different time points using a cox regression model with time-dependent coefficient.
A total of 343,397 patients with IDC and 39,859 patients with ILC were included. Patients with ILC had more advanced-stage disease (stage II, 35% vs. 34%; stage III, 16% vs. 11%) and a higher rate of hormone receptor–positive disease (97% vs. 81%). Compared with patients with IDC, patients with ILC had better BCSS in the first five years (HR = 0.71; P < 0.001) but worse BCSS in later years (HR = 1.30, P < 0.001 in years 6–10; HR = 1.75, P < 0.001 in years 11–15; and HR = 2.17, P < 0.001 in years 16–20).
Patients with ILC survive better in early years but worse in later years compared with patients with IDC. Future studies are required to identify patients with ILC who are at risk of late recurrence or mortality.
The results of this study add to the currently conflicting literature of survival of ILC and demonstrate the importance of evaluating novel therapeutic approaches and extended therapy for patients with ILC.
